Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MBOT
stocks logo

MBOT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.070
-65%
--
--
-0.090
+12.5%
--
--
-0.090
-10%
Estimates Revision
The market is revising Downward the revenue expectations for Microbot Medical Inc. (MBOT) for FY2025, with the revenue forecasts being adjusted by -94.67% over the past three months. During the same period, the stock price has changed by -32.79%.
Revenue Estimates for FY2025
Revise Downward
down Image
-94.67%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.33%
In Past 3 Month
Stock Price
Go Down
down Image
-32.79%
In Past 3 Month
Wall Street analysts forecast MBOT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBOT is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast MBOT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBOT is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.460
sliders
Low
12.00
Averages
12.00
High
12.00
Current: 2.460
sliders
Low
12.00
Averages
12.00
High
12.00
Roth Capital
Kyle Bauser
Buy
initiated
$5.50
2025-12-03
New
Reason
Roth Capital
Kyle Bauser
Price Target
$5.50
2025-12-03
New
initiated
Buy
Reason
Roth Capital analyst Kyle Bauser initiated coverage of Microbot Medical with a Buy rating and $5.50 price target. The firm says the company's Liberty Endovascular Robotic System achieved FDA clearance in September and has begun commercial use in select U.S. hospitals ahead of a full market release in April 2026. Roth thinks the technology will be useful within procedures that require navigation of complex vascular anatomy while also reducing physical strain and radiation exposure.
H.C. Wainwright
Raghuram Selvaraju
Buy
maintain
$9 -> $12
2025-09-11
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$9 -> $12
2025-09-11
maintain
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Microbot Medical to $12 from $9 and keeps a Buy rating on the shares after the FDA granted 510(k) clearance for the company's Liberty System. This is the first FDA-approved, single-use, remotely operated robotic system for peripheral endovascular procedures, the analyst tells investors in a research note. The firm says the initial addressable market comprises 2.5M peripheral endovascular procedures annually in the U.S.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$9
2025-04-10
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$9
2025-04-10
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$7 → $9
2025-01-24
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$7 → $9
2025-01-24
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Microbot Medical Inc (MBOT.O) is -7.69, compared to its 5-year average forward P/E of -4.57. For a more detailed relative valuation and DCF analysis to assess Microbot Medical Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.57
Current PE
-7.69
Overvalued PE
2.45
Undervalued PE
-11.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.08
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.49
Undervalued EV/EBITDA
-0.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
812.49
Current PS
0.00
Overvalued PS
5378.75
Undervalued PS
-3753.76
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MBOT News & Events

Events Timeline

(ET)
2025-11-26
08:32:44
Microbot Medical Reveals Emory University as the First Hospital to Implement LIBERTY
select
2025-11-05 (ET)
2025-11-05
08:34:43
Microbot Medical Launches LMR for Its LIBERTY System in the United States
select
2025-10-14 (ET)
2025-10-14
08:34:49
Microbot Medical Collaborates with 3PL Firm to Launch LIBERTY System
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-28Benzinga
HC Wainwright & Co. Affirms Buy Rating for Microbot Medical, Keeps $12 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and resources.

  • Market Winning Tools: The platform is designed to provide traders with the tools they need to succeed in the markets every day.

[object Object]
Preview
3.5
11-26Newsfilter
Microbot Medical Launches LIBERTY Robotic System, First Hospital Adoption Announced
  • First Hospital Adoption: Emory University Hospital becomes the first to adopt the LIBERTY robotic system, marking a significant advancement in its application for peripheral vascular procedures and enhancing the hospital's leadership in interventional radiology.
  • Market Release Plans: Microbot plans a full market release of the LIBERTY system at the Society of Interventional Radiology (SIR) conference in April 2026, aiming to accelerate market adoption through showcasing its innovative technology and driving growth in the medical robotics sector.
  • Technological Innovation: LIBERTY is the world's first FDA-cleared single-use, remotely operated robotic system designed for peripheral interventions, aimed at improving procedural precision while reducing radiation exposure and physical strain on clinicians, thereby enhancing patient care quality.
  • Strategic Collaboration: Microbot is collaborating with Emory University Hospital to establish an Endovascular Robotics Program, supporting clinicians in delivering precise care for procedures like liver tumor embolization, which further solidifies the company's strategic position in the medical robotics market.
[object Object]
Preview
5.0
11-05Newsfilter
Microbot Medical® Launches Limited Market Release of LIBERTY® Endovascular Robotic System in the U.S.

  • Introduction of LIBERTY®: Microbot Medical Inc. has launched the LIBERTY® Endovascular Robotic System in the U.S. following FDA clearance, focusing on a Limited Market Release (LMR) to gather insights from high-volume users.

  • Positive Reception: The company has received overwhelmingly positive feedback from physicians and hospital administrators, validating the demand for LIBERTY® and supporting its commercialization efforts.

  • Commercial Readiness: To ensure a successful LMR, Microbot has secured a third-party logistics partner and expanded its commercial leadership team, aiming for a Full Market Release (FMR) at the Society of Interventional Radiology meeting in April 2026.

  • Future Outlook: The company emphasizes its commitment to innovation in endovascular procedures and acknowledges potential risks associated with the commercialization of LIBERTY®, including market conditions and regulatory uncertainties.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Microbot Medical Inc (MBOT) stock price today?

The current price of MBOT is 2.46 USD — it has decreased -1.2 % in the last trading day.

arrow icon

What is Microbot Medical Inc (MBOT)'s business?

Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.

arrow icon

What is the price predicton of MBOT Stock?

Wall Street analysts forecast MBOT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBOT is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Microbot Medical Inc (MBOT)'s revenue for the last quarter?

Microbot Medical Inc revenue for the last quarter amounts to -3.86M USD, increased 17.00 % YoY.

arrow icon

What is Microbot Medical Inc (MBOT)'s earnings per share (EPS) for the last quarter?

Microbot Medical Inc. EPS for the last quarter amounts to -3854000.00 USD, increased 39.69 % YoY.

arrow icon

What changes have occurred in the market's expectations for Microbot Medical Inc (MBOT)'s fundamentals?

The market is revising Downward the revenue expectations for Microbot Medical Inc. (MBOT) for FY2025, with the revenue forecasts being adjusted by -94.67% over the past three months. During the same period, the stock price has changed by -32.79%.
arrow icon

How many employees does Microbot Medical Inc (MBOT). have?

Microbot Medical Inc (MBOT) has 21 emplpoyees as of December 05 2025.

arrow icon

What is Microbot Medical Inc (MBOT) market cap?

Today MBOT has the market capitalization of 165.21M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free